Older adults, sarcopenia risk, and the trade-off nobody quantifies — the long version posts 61–70

Post #59 describes the usual case. This is about the unusual one.

Body weight at the extremes of the studied range affects exposure and the trials rarely reported enough to say by how much.

Adding the measurement that post #59 says would settle it.

Hypoglycemia risk: in people already on insulin or sulfonylureas, adding a GLP-1 agonist requires insulin dose reduction and close monitoring for hypoglycemia. This is manageable with attention.

Reading this Older adults thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.

The number people quote for Older adults is a central estimate presented without its interval, and the interval is wide enough that the estimate is nearly uninformative on its own.

Helpful, and short, which on this subject is harder than long.

The most useful contribution here is usually a citation to whichever published document comes closest, with a plain statement of how far it is from the question.

Noting that I have skin in this question and have tried to discount for it.

One caution on Older adults: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.

Post #67 is right about the mechanism and I think understates the practical bit.

Older adults were included in the trials in smaller numbers than their share of the eventual population, so precision in that subgroup is poor.

I would be cautious about generalising from the Older adults example above. It is a good example. It is one example.

What I would check first on Older adults is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.